These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2393260)

  • 41. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy.
    Soman A; Honeybourne D; Andrews J; Jevons G; Wise R
    J Antimicrob Chemother; 1999 Dec; 44(6):835-8. PubMed ID: 10590288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Penetration of lomefloxacin into human prostatic tissue.
    Leroy A; Grise P; Dhib M; Valtchev B; Fillastre JP
    Urology; 1991 Aug; 38(2):192. PubMed ID: 1877143
    [No Abstract]   [Full Text] [Related]  

  • 43. Penetration of enoxacin into human bronchial mucosa.
    Marlin GE; Braude PD; Whelan AJ; Somogyi AA
    Am Rev Respir Dis; 1986 Dec; 134(6):1209-12. PubMed ID: 3466562
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A ten-laboratory study of lomefloxacin (NY-198 or SC 47111) antimicrobial activity in Argentina.
    Bianchini HN; Sarachian B; Fernandez A; Paolasso R; Kaufman C; Notario R; Porven G; Ingaramo RA; Perez S; Ferrero SM
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):45S-50S. PubMed ID: 2676328
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum protein binding of lomefloxacin, a new antimicrobial agent, and its related quinolones.
    Okezaki E; Terasaki T; Nakamura M; Nagata O; Kato H; Tsuji A
    J Pharm Sci; 1989 Jun; 78(6):504-7. PubMed ID: 2760827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lomefloxacin clinical pharmacokinetics.
    Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
    Clin Pharmacokinet; 1993 Jul; 25(1):6-19. PubMed ID: 8394795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model.
    Rustige C; Wiedemann B
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1107-11. PubMed ID: 2118324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing.
    Mant TG
    Am J Med; 1992 Apr; 92(4A):26S-32S. PubMed ID: 1316066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of lomefloxacin in patients with cirrhosis.
    Lebrec D; Gaudin C; Benhamou JP
    Am J Med; 1992 Apr; 92(4A):41S-44S. PubMed ID: 1316069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function.
    Leroy A; Fillastre JP; Humbert G
    Antimicrob Agents Chemother; 1990 Jan; 34(1):17-20. PubMed ID: 2327756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of lomefloxacin (SC-47111) against enterobacteriaceae, enterococci and staphylococci.
    Cornaglia G; Ligozzi M; Pelosi E; Canepari P; Fontana R
    J Chemother; 1989 Apr; 1(2):84-90. PubMed ID: 2786558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.
    Jones RN; Aldridge KE; Barry AL; Fuchs PC; Gerlach EH; Pfaller MA; Washington JA
    Diagn Microbiol Infect Dis; 1988 Aug; 10(4):221-40. PubMed ID: 3072151
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea.
    Segreti J; Nelson JA; Goodman LJ; Kaplan RL; Trenholme GM
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1385-7. PubMed ID: 2802563
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of lomefloxacin on theophylline pharmacokinetics.
    Nix DE; Norman A; Schentag JJ
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1006-8. PubMed ID: 2675751
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative penetration of lomefloxacin and other quinolones into human phagocytes.
    Perea EJ; García I; Pascual A
    Am J Med; 1992 Apr; 92(4A):48S-51S. PubMed ID: 1316071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria.
    Hoban D; Grabowski M; Koss J; Weselowski V
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):77S-82S. PubMed ID: 2791502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses.
    Mattina R; Bonfiglio G; Cocuzza CE; Gulisano G; Cesana M; Imbimbo BP
    Chemotherapy; 1991; 37(6):389-97. PubMed ID: 1662127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of lomefloxacin in renally compromised patients.
    Blum RA; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Penetration of ofloxacin into bronchial secretions.
    Symonds J; Bone M; Turner A; Javaid A
    Drugs; 1987; 34 Suppl 1():33-6. PubMed ID: 3481325
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of lomefloxacin (NY-198 or SC 47111).
    Shah PM; Müller S; Kipp J; Stille W
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):97S-101S. PubMed ID: 2791506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.